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1

Abstract

2

Fifty per cent of first-degree relatives of index cases with familial

3

hypercholesterolemia (FH) inherit the disorder. Despite cascade screening being the

4

most cost-effective method for detecting new cases, only a minority of individuals

5

with FH are currently identified. Primary care is a key target area to increase

6

identification of new index cases and initiate cascade screening, thereby finding

7

close relatives of all probands. Increasing public and health professional awareness

8

about FH is essential.

9

In the United Kingdom and in Australia, most of the population are reviewed by a

10

General Practitioner (GP) at least once over a three-year period, offering

11

opportunities to check for FH as part of routine clinical consultations. Such

12

opportunistic approaches can be supplemented by systematically searching

13

electronic health records with information technology tools that identify high risk

14

patients. GPs can help investigate and implement results of this data retrieval.

15

Current evidence suggests that early detection of FH and cascade testing meet most

16

of the criteria for a worthwhile screening program. Among heterozygous patients the

17

long latent period before the expected onset of coronary artery disease provides an

18

opportunity for initiating effective drug and lifestyle changes. The greatest challenge

19

for primary care is to implement an efficacious model of care that incorporates

20

sustainable identification and management pathways.

21

Word count: 209

22
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1

Introduction

2

There is a general lack of public1-3 and health professional4-7 awareness of

3

heterozygous Familial hypercholesterolaemia (FH) as a common, autosomal

4

dominant disorder of lipid metabolism8-10. FH can cause premature coronary artery

5

disease (CAD) if left untreated11 with up to 50% of males likely to develop CAD by

6

age 50 years and 30% of females similarly affected by age 60 years. Owing to a

7

genetic defect in the low-density lipoprotein (LDL)-receptor pathway, affected

8

patients cannot clear LDL particles from the circulation, which untreated leads to life-

9

long, accumulation of low-density lipoprotein cholesterol (LDL-c) in plasma and

10

accelerated atherosclerosis8, 10, 12, 13. FH patients cannot be managed solely by diet

11

and lifestyle modifications. The cumulative cholesterol burden in homozygous FH is

12

much greater as the condition is inherited from both parents8. Such patients develop

13

severe life-threatening coronary heart disease (CHD) and other vascular

14

complications in late childhood and adolescence if not recognised and treated.

15

FH affects 1 in 250 of the population14-16. Such a prevalence would expect to yield

16

over 30 million patients worldwide, 240,000 in the United Kingdom (UK) and 90,000

17

in Australia. With over 85% of the Australian and UK population attending a General

18

Practitioner (GP) at least once a year17-19, opportunities exist for primary care to play

19

a much more active role in the detection and care of FH patients in the future.

20

Despite increasing knowledge of the clinical hallmarks of FH – elevated LDL-c levels,

21

family and personal history of premature coronary heart disease, premature arcus

22

cornealis and tendon xanthomata, most cases of FH are still not being recognised1, 9,

23

12.

24

explanations have been offered to explain these missed opportunities for diagnoses

Amongst patients recognised as having FH, most remain under-treated9. Various
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1

including busy clinical settings at tertiary and primary care level, pressure on bed

2

availability and early discharge policies from hospitals.20 Increasing complexity and

3

amount of multimorbidity21 in routine clinical presentations to GPs make recognition

4

of FH especially challenging22.

5

Coronary care units are other settings where FH may be identified. Patients with

6

early onset of symptoms of ischemic heart disease may be admitted for further

7

assessment and treatment. Such encounters will usually involve a shared care role

8

for GPs, cardiologist and hospital specialist. Evidence to date suggests these are

9

often missed opportunities for FH diagnoses in some patients20.

10

Effective treatment is available and earlier beliefs that regression of atheromatous

11

plaques could not be achieved are being challenged with studies showing intensive

12

drug therapy can have a beneficial effect23, 24. Compliance with optimum treatment,

13

usually statins, can be problematic at both patient and health professional levels12, 25

14

and needs regular review and re-enforcement.

15

We review the potential to increase the role of primary care in the detection and care

16

of FH.

17

International guidelines and approaches

18

The Consensus Statement of the European Atherosclerosis Society9 and the

19

International FH Foundation26 both recommend that most patients with FH should be

20

managed in the primary care setting and preferably in the family context. They

21

advise that there should be provision for more complex cases, including children, to

22

be managed through specialist lipid or FH clinics.

23

It is increasingly recognised that childhood and early adolescence offer the most

24

favourable timeframe for diagnosing FH as well as introducing and maintaining
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1

lifelong treatment and management strategies3, 9, 12. To achieve such radical care

2

from a young age will require a shift in community and health professional

3

perceptions of FH and its effects on the young. Little attention has been given to date

4

to screening for FH in general practice where most affected patients are found.

5

In countries with a history of dedicated screening programs, such as the Netherlands

6

and Norway, the outcomes in terms of newly diagnosed FH index cases and

7

cascade tested relatives are much higher than countries lacking any formal

8

screening program (usually <1%)9, 27.

9

Evidence suggests that cascade screening of close relatives is generally highly

10

acceptable and does not impact on quality of life27. The Dutch FH cascade screening

11

program operated between 1994 and 2014 using the services of genetic field

12

workers and was very successful27. Since the program was modified due to changes

13

in the Dutch Health System, numbers diagnosed have dropped27.

14

Most Australian and UK primary care practices are fully computerised, often with

15

links to pathology providers and hospital services, thus lending themselves to

16

electronic examination of patient databases for chronic hereditary conditions such as

17

FH. In Australia, laboratory alerts either through a direct telephone call28 from the

18

chemical pathologist to GP or through flagging of raised lipids reports raising

19

possibility of FH29, 30 have been successful. Other Australian community-based

20

initiatives include examining general practice and laboratory databases31, use of

21

algorithm32 or data extractions tools33.

22

In the UK, the accessibility to most GPs of regionally located specialist lipid clinics

23

has provided valuable additional support for primary care management34 while GP-

24

based approaches involving database searches have also been trialled35, 36.
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1

In Slovenia, the use of universal screening for children aged over 5 years has been

2

introduced to help with the detection of FH37, but the practicalities and cost-

3

effectiveness remain to be confirmed. In the United States, universal screening of

4

cholesterol at age 9 to 11 has been endorsed by the American Academy of

5

Pediatrics and the National Lipid Association (NLA), but has been incompletely

6

undertaken and cost benefit analyses of this approach have not been performed65.

7

Screening for FH in primary care

8

Primary care based screening for FH fulfils many of the revised Wilson and Jungner

9

criteria38, including the updated Australian Government population screening

10

guidelines39 (See Table 1)

11

Advances in approaches to screening in primary care

12

Primary care can make a more substantial contribution to the detection and care of

13

FH33, 36, 40. Tests to help diagnose FH are simple and acceptable to the public, the

14

available treatment is effective and case finding can take place in clinical practice12.

15

The latent period between potential diagnosis of FH (preferably in childhood or

16

adolescence) and the onset of CHD (early middle age) is in theory sufficient to allow

17

effective, lifelong treatment to be instituted before atheromatous plaque development

18

occurs. This time-frame is critical to facilitate an improved primary care role in FH

19

recognition12.

20
21

Research on strategies to identify FH in primary care:
1. Child-parent screening / Reverse cascade screening

22

Wald et al.40 examined the efficacy and feasibility of child-parent screening for FH in

23

primary care practices. They undertook the screening at routine immunisation
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1

attendances by children aged 1 – 2 years at 92 general medical practices in the

2

United Kingdom over a three-year period. A total of 84% of parents agreed to the

3

heel-stick capillary blood sampling offered to test for FH. The child provided the

4

screening entry point at an age identified as the most discriminatory for the

5

measurement of cholesterol41. Once the child is identified as having FH, one of the

6

parents will also harbour the condition enabling two generations to be effectively

7

screened as part of the process.

8

For the 10,000 children screened, based on cholesterol levels, 40 children and 40

9

parents were identified as positive for FH, at high risk for cardiovascular disease

10

(CVD) and offered appropriate treatments40. The population prevalence of children

11

found to have FH was 1 in 270. A total of 32 of the 40 children screening positive for

12

FH were found to have a genetic mutation while 8 did not. Child-parent screening

13

was seen as a simple, effective and practical method to examine a population for the

14

presence of FH40.

15
16

2. Systematic and opportunistic screening and case finding in general
practice

17

Primary care can significantly improve the identification and management of FH in

18

the general population3, 9, 12, 31 where the prevalence is about twice that previously

19

estimated14-16, 26. A prevalence of 1 in 250 would yield 40 individuals with FH in a

20

practice population of 10,000 patients. Most practices of this size would not realise

21

this potential at risk group exists. For primary care to improve FH detection, greater

22

health professional awareness of the significance of markedly elevated cholesterol

23

levels in high risk patients, a family or personal history of premature CAD or death

24

plus recognition of other tell-tale stigmata of FH, will be necessary1, 3.
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1

Extra workloads

2

Opportunities to increase detection of FH in general practice are becoming more

3

sophisticated. New data extraction tools employing algorithms of the phenotypic

4

features of FH (Dutch Lipid Clinic Network (DLCN)42, Make Early Diagnosis to

5

Prevent Early Deaths (MEDPED)43 and Simon-Broome (S-B) criteria44) can minimise

6

practice workloads while still focussing attention on detecting high risk patients.

7

In Australia, there have been attempts at improving detection and management of

8

FH in the primary care sector33, 45-47. Models of care, which in the past have focussed

9

on tertiary level hospital lipid clinics3, are now looking at a greater involvement from

10

primary care especially for patients without additional risk factors22, 41.

11

Phenotypic v genetic testing

12

The DLCN criteria (DLCNC) score42 is the preferred tool in Australia to help with

13

phenotypic diagnosis of FH26. Cost, geographic and migration factors, plus lack of

14

population density across most of the continent, are major handicaps towards use of

15

genetic testing for all suspected FH patients22. The same barriers also preclude the

16

widespread use of dedicated field workers27 to undertake systematic contact tracing

17

of close relatives. A more pragmatic approach involving use of the DLCNC score in

18

the primary care setting is currently being trialled in Australia47.

19

The use of genetic testing in the UK compared with the phenotypic approach

20

advocated in Australia and in the United States offers an interesting comparison34.

21

Current National Institute for Health and Care Excellence (NICE) guidelines17 favour

22

the critical importance of genetic testing to confirm monogenic FH. Only patients

23

testing positive to the FH gene mutation will be given the diagnosis of FH. Other

24

patients with the clinical features of FH (phenotypic) but no established mutation will
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1

be designated as ‘polygenic hypercholesterolemia’. NICE guidelines17 also advocate

2

that only relatives of genetically positive index cases should be offered genetic

3

testing to establish mutation positive FH. The obvious downside is that with over

4

1700 known FH mutations48, not all are amenable to genetic testing and up to 40%

5

may be missed9.

6

National Institute for Health and Care Excellence (NICE) guidelines

7

In UK, the original NICE Guideline CG7117 advised suspicion of FH diagnosis in

8

adult if raised total cholesterol (> 7.5 mmol/l) especially with personal or family

9

history of premature CHD. GPs should exclude secondary causes of FH, undertake

10

detailed family history that is regularly updated and undertake thorough clinical

11

examination to check for signs of elevated cholesterol, such as, tendon

12

xanthomata34. Patients with ’definite’ or ‘possible’ FH on S-B criteria should be

13

referred to specialist with FH expertise to confirm diagnosis, advise on management

14

and help with co-ordination of cascade testing among close relatives. Many patients

15

identified as ‘possible’ FH will not be confirmed as having the condition49. The 2017

16

NICE guidelines advise systematic searches of patient records for cholesterol over

17

9mmol/l as these have over 25% chance of having FH17.

18

The absence of suitable infrastructure in primary care to assist with cascade testing

19

of relatives is a major handicap2. Serious deficiencies have been found in patient

20

knowledge about FH, their risk of a major cardiac event and the mode of inheritance

21

across generations50.

22

General practice search strategies

23

Gray et al.35 undertook computer-based searches to look for likely FH patients at a

24

primary care centre of 12,000 patients in South London. A total of 402 individual
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1

patients were identified for review. After record review and using the DLCNC

2

score42, they identified 12 patients who scored 8 and above (’definite’ FH); eight who

3

score between 6 and 8 (‘probable’ FH) and a further 47 patients who scored between

4

3 and 5 (‘possible’ FH). Thus, a total of 20 patients met the criteria for ‘definite’ or

5

‘probable’ FH in the study. No cases with tendon xanthomata were found.

6

All patients with FH were noted to have early CAD and the authors concluded this

7

finding as the key to reaching a diagnosis of FH. Commencement of treatment for

8

elevated lipids with statins was noted to occur without the potential for FH being the

9

key diagnosis being considered. This lost opportunity to screen close family

10

members for the condition could have contributed to avoidable mortality in the

11

circumstances35.

12

The time factor involved was a limiting factor. Each manual search of medical

13

records took about 30 minutes and amounted to 201 hours of additional work to

14

examine the records of the 402 patients identified as being at higher risk35. The use

15

of electronic screening tools combined with efficient clinical follow-up by GP and/or

16

PN can offer a more time- and cost-effective systematic approach to identify FH

17

patients in the primary care setting.

18

Familial Hypercholesterolaemia Case Ascertainment Tool (FAMCAT)

19

To improve and simplify identification of FH in British primary care electronic health

20

records, a case ascertainment tool - Familial Hypercholesterolaemia Case

21

Ascertainment Tool (FAMCAT)36 was developed to identify those with the highest

22

probability of the condition, with predictive accuracy (AUC) of 86%. FAMCAT allows

23

more efficient use of limited resources by identifying those that need further clinical

24

assessment, undergo referral for diagnosis and commencement of appropriate
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1

preventative care for the future. Because patient health data is generally well

2

recorded in the electronic medical records in general practices, FAMCAT uses coded

3

variables to enhance the discriminatory information to identify the highest risk

4

patients for further evaluation. This has been integrated into a national quality

5

improvement tool51.

6

TARB-Ex

7

In Australia, TARB-Ex33 is an electronic research screening tool that uses

8

information from regular general practice databases to identify patients with high

9

DLCN scores who are then invited to attend the practice for further clinical

10

investigation and phenotypic diagnosis. It was developed using Structured Query

11

language (SQL) technology and integrated into Best Practice clinical software52. It

12

has the capacity to be adapted for other SQL-based practice software including

13

Medical Director, ZedMed, MedTech, Practix and Monet which taken together

14

account over 90% of clinical software in Australia.

15

The performance of TARB-Ex was evaluated against a manual assessment by a GP

16

of a subset of patients attending the practice33. Overall, results suggested that

17

TARB-Ex was a fast and effective method for systematically identifying patients

18

attending the practice with potential high risk of FH to enable further clinical

19

investigation. Additional costs to the practice in terms of manpower and GP workload

20

were minimised. TARB-Ex showed high sensitivity, specificity and negative

21

predictive power, comparing favourably with manual review in just a fraction of the

22

time – 10 minutes v 60 hours for manual review33.

23

TARB-Ex integrates well into regular clinical practice. A GP, Practice Nurse (PN) or

24

Practice Manager can undertake the initial screening process prior to recall for
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1

clinical review. GP and PN involvement is limited to reviewing medical records of

2

patients identified by TARB-Ex with high DLCNC scores and at risk for FH, exclude

3

confounding secondary causes and decide which patients merit recall for clinical

4

review.

5

Limitations of screening tools

6

All electronic screening tools are only as effective as the quality of the medical and

7

blood pathology information stored in practice databases. The experience in UK and

8

Australia shows family histories are poorly recorded for many patients53-57 and is an

9

acknowledged limitation of GP-based databases in comparison with hospital-based

10
11

admissions and discharge summaries.
3. Community pathology alerts to GPs

12

Attempts have been made to link the performance of community pathology

13

laboratories and general practice databases29, 31 to help identify patients with specific

14

indicators suggestive of FH and facilitate clinical follow-up. Evidence shows that a

15

telephone call or alerting message from a chemical pathologist to the GP could have

16

a powerful impact on whether an elevated cholesterol level was better investigated28.

17

With GPs requesting over 90% of LDL-c levels in Australia, the opportunity for more

18

innovative screening at the primary care level could be improved29, 30.

19

The combination of greater reductions to target LDL-c levels and better use of

20

specialist services could facilitate improvements in FH recognition and care. The

21

shared care approach with GP management for lower to intermediate risk patients

22

and specialist support for higher risk and more complex cases should be a logical

23

development in care strategy.

24

4. Use of health checks
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1

FH is ideally suited to use of periodic health checks and subsequent care plan

2

management as part of a strategic approach to manage this chronic disease in

3

general practice. Much emphasis with FH to date has focussed on ‘top-down’

4

approaches with identification and management primarily in tertiary hospital clinics

5

and specialist care. In the early, asymptomatic phase of FH, early diagnosis and

6

appropriate diet, lifestyle and drug interventions can be provided at the primary care

7

level. Easy access to primary care services and regular follow-up checks at local

8

practices can be provided. In Australia, care plans and 45-49 year-old health

9

checks58 developed by GPs and PNs, can be supported by other health

10

professionals including dieticians, exercise physiologists and clinical psychologists

11

while cardiologists, lipid specialists, endocrinologists and paediatricians can also

12

contribute as required.

13

Many care plans have traditionally been viewed as mainly targeting the degenerative

14

processes associated with ageing, diabetes, ischemic heart disease and strokes. FH

15

can legitimately be added as a chronic lifelong condition that is well suited to a

16

planned approach and management in primary care. Specialist help should always

17

be available for more complex and difficult to manage patients and children.

18

In the UK, the 40 – 74 year-old age group health checks58, 59 for patients with no

19

recorded chronic health condition could be utilised to assess for FH risk. Patients

20

with total cholesterol levels above 7.5mmol/l, should be targeted by GPs to

21

undertake further investigations34, 60.

22

5. Improve public awareness of FH

23

Improving public awareness of the possibility of FH, especially in the community

24

setting, needs to be addressed3, 50. Many families may be aware of premature CVD
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1

deaths in their own households but the significance of these past events and the

2

potential future risk to their own health is often not fully grasped. Young off-spring of

3

affected patients are likely to feel entirely healthy and lacking in symptoms and see

4

no reason to commence life-long treatment for a condition they perceive as posing

5

no immediate or potential threat. It may take on some relevance when a friend or

6

colleague develops a life-threatening heart attack at a young age and their own

7

potential risk is suddenly brought into sharper focus22. High risk patients with

8

potential FH or known FH patients who refuse or are non-compliant with best

9

practice medications and lifestyle modifications, should be offered an ‘open door’

10
11

approach to be seen early if they change their mind re future treatments.
6. Improve health professional awareness of FH

12

Despite increasing knowledge about the prevalence and risks of FH, many health

13

professionals do not make a connection between FH and the patient’s presenting

14

condition3, 6, 50. A better appreciation of the underlying genetic nature of the

15

disease10, 13, 61 and the fact that it will not be solely responsive to dietary and lifestyle

16

intervention is needed.

17

The current best management approach is through use of high intensity statins from

18

a young age1, 9, 11, 12, 14, 26, 62. The lifetime increased accumulation of LDL-c means

19

that the relative risk from FH makes the use of absolute CVD risk calculators63

20

inappropriate in patients with FH and they should not be used1, 9, 11, 14, 26. Compliance

21

with lifetime statin therapy may be a significant problem especially if family

22

perceptions of such treatment is an issue12. GPs can play a major role in this area.

23
24

7. Improve support in primary care for cascade screening of close relatives
of index cases
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1

Cascade screening of close family relatives of known index cases is recognised as

2

the most efficient and cost-effective approach for identifying new FH patients3, 9, 64-66.

3

The evidence to support cascade testing of relatives is based on specialist centre

4

approaches rather than screening from primary care3. The UK National Health

5

Service (NHS) has recognised the difficulties posed by a lack of suitable

6

infrastructure in primary care to undertake systematic cascade screening, and

7

recommend that it should be undertaken through specialist centres instead17, 34.

8

Evidence from the Netherlands showed the success of using genetic field workers to

9

target close relatives of new index cases in a systematic fashion27, 67. The Dutch FH

10

program which sought to find all FH patients, was centrally controlled and involved

11

all specialists in cardiovascular care as well as all GPs, and had extensive media

12

and scientific journal exposure to increase awareness at the general population and

13

health professional levels27.

14

Experience from the Danish General Population study on FH14 suggests that

15

development of national models of care, and health policy integrating care between

16

GPs and specialists, would achieve the best outcomes for individuals and families

17

with FH.

18

Density of population in close geographic proximity can help the cascade screening

19

of relatives, with families in more remote locations and migrant families at a much

20

greater risk of having a less effective service22, 68.

21

Where does primary care screening for FH fit into Models of Care?

22

The role of primary care in the detection and care of patients with FH is evolving but

23

no consensus exists on the optimum screening strategy, on how best to integrate

24

primary and specialist level care32, on genetic versus phenotypic testing3, 34, 69, on
Page 15 of 29

1

childhood screening70, on sustainable methods of cascade testing close relatives of

2

index cases71 and on recording family history72, 73. Table 2 provides suggested

3

strategies for measuring cholesterol and genetic testing by age in a primary care

4

practice. Low levels of public and health professional awareness of the disorder is

5

central to this uncertainty as is poor compliance once a diagnosis is made9, 50.

6

The traditional model of care for FH is based on the chronic care model3, 32 and aims

7

to deliver the right treatment, for the right patient, at the right time, by the right team

8

across the continuum of care. Of necessity, this will involve a major contribution from

9

primary care but patients with the condition are not being recognised during routine

10

clinical encounters1, 9, 14. The current infrastructure in primary care makes cascade

11

screening very challenging3, 22. Research in UK estimated an upper limit of 40%

12

success rate might be possible and that involved specialist centre supports34.

13

Attempts at cascade testing in primary care have been limited but the option is being

14

canvassed47. Tertiary hospital models of service delivery are unlikely to be

15

sustainable in primary care. Targeting high risk individuals with family history of

16

premature CVD would be useful9, 32, 33, 36.

17

Unanswered questions on primary care detection of FH

18

From this review, we propose new lines for research based on a framework

19

proposed by Gidding et al in an American Heart Association statement on FH1.

20

Table 3 summarises topics that cover new diagnostic applications, population

21

science, clinical research, patient-centric questions and models of care. Public

22

consultation regarding all research aspects, particularly detection methods such as

23

universal screening is recommended74.
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1

The challenge of identifying new index cases of FH in the community setting75

2

requires much more than opportunistic case finding during routine GP consultations,

3

followed by cascade testing of close family relatives76. Universal screening

4

approaches together with reverse cascade testing in the child-parent setting has

5

shown good potential,40, 41, 77 but should be seen as part of a multi-faceted approach

6

across community and hospital clinic settings that is integrated into routine clinical

7

care75.

8

The potential of FH Registries78-81 and improved coding for FH needs to be linked to

9

screening approaches and establishment and harmonisation of the clinical

10

diagnosis1, 26, 77. Primary care has a key role to play but lacks the infrastructure and

11

supports offered by hospital lipid clinics. Such support will be critical if a sustainable

12

primary care based model of care is to be established1.

13

Conclusion

14

Primary care can improve the detection and care of FH patients through an efficient,

15

cost-effective and sustainable approach acceptable to patients, families and health

16

professionals1, 3, 9. This approach should straddle the entire continuum of care3, 9, 32,

17

82

18

pathology, genetics and allied health. FH is best diagnosed in childhood or early

19

adolescence1, 9, 12, 14 followed by cascade testing of family members with 50%

20

detection rates expected among first degree relatives1, 26, 64, 65. This allows for timely

21

institution of lifelong medication and lifestyle changes to prevent the early

22

development of atherosclerosis3, 9, 12,. A shared care model involving primary care for

23

low risk and specialist support for high risk and difficult to manage patients, would be

24

ideal.

– general practice, lipid specialists, cardiology, paediatrics, endocrinology,
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1

Increased awareness of potential FH among the public and among health

2

professionals is required1, 50. GPs and PNs should grasp the implications of a

3

diagnosis of FH1, 3, 9, 12, 50, and the need for follow-up checks to monitor compliance

4

and treatment targets1, 9, 12, 14, 50. Patients need re-enforcement that achieving LDL-c

5

targets will reduce their cumulative lifetime risk for premature CAD12, 50. Chronic

6

disease care plans are a cost-effective way for general practice to manage such

7

care22, 58.

8

At community level, families with history of early heart disease should be especially

9

targeted1, 3, 12. Primary care with its ease of access and frequent patient contact can

10

help in this regard18, 19 Patients and families with FH need reminding that they are at

11

significantly greater risk for CVD compared to those without50. Better education for

12

the newly diagnosed young and regular follow-up to ensure compliance will be

13

necessary12, 82. Wald et al’s40 targeting of 92 general practices to universally screen

14

over 10,000 toddlers aged 1-2 years at routine immunisation attendances with 84%

15

parent approval offers hope for the future. Childhood detection allowed reverse

16

cascade screening of parents (50% pickup) and saved lives40.

17

A combination of opportunistic case-finding, systematic and universal screening of

18

general practice databases33, 36, 47 increased public and health professional

19

awareness of the disease1, 3, 9, 14, and better education and treatment knowledge

20

among primary care teams1, 50, especially the need for lifetime care with specialist

21

support, is required.

22
23
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Table 1. Screening criteria for FH and role and opportunities for primary care
Screening Criteria
(1) The screening
programme should
respond to a
recognised need
(2) The objective of
screening should be
defined at the outset.
(3) There should be a
defined target
population.

(4) There should be
scientific evidence of
screening programme
effectiveness.
(5) The programme
should integrate
education, testing,
clinical services and
programme
management.
(6) There should be
quality assurance,
with mechanisms to
minimise potential
risks of screening.

(7) The programme
should ensure
informed choice,

•
•

Over 85% of patients with FH have not been
identified2.
Without treatment CHD develops1, 3, 9.

•

Identification of patients at very high risk of
premature CHD1, 3, 9.
• High intensity lipid lowering treatment can lead to
48% reduction in CHD mortality1, 3, 9.
Less consensus, but is based on an interplay of an
individual’s cholesterol levels and family history of
premature coronary heart disease, familial
hypercholesterolemia and/or raised cholesterol eg:
• Cholesterol levels > 9.3 mmol/l indicated FH in 28%
of patients60
• Cholesterol levels > 7.5mmol/l should trigger further
assessment of FH2, 35
• Personal or family history of premature CHD17
• Diagnostic criteria such as the DLCN42, MEDPED43
and S-B criteria44
Case series and interventional studies49 show
improvement in the number of new cases identified with
possible or definite FH.
Several countries integrate preventative programmes
and care pathways from primary to specialist care 1, 3, 9
(see section “Potential approaches to screening in
primary care”).
•

Lipid tests are available to internationally
recognised standard (currently ISO 17043 in UK
and NPAAC83 in Australia)
• Family history recording of a three generation
pedigree is standard in specialist care but the
requirement for primary care is unclear. This could
be a detailed family history collection or a less
sensitive method of a few direct questions84
• Genetic testing will require agreed standard of
testing and interpretation prior to adoption.
Currently the gold standard is NGS69, 85, 86 as a cost
saving method87,88 but risks missing phenotypic
FH3.
• Patients offered genetic testing within standard
ethical framework including fully informed of the
implications of testing 3, 89.
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confidentiality and
respect for autonomy.

•

(8) The programme
should promote
equality and access to
screening to the entire
target population.
(9) Programme
evaluation should be
planned from the
outset

Identification of FH in primary care could involve
opportunistic identification at review by GP or through
programmes such as the UK national vascular check
programme59 which has improved assessment in
deprived communities90.
From inception of an FH screening programme in
primary care, key measures assessed should include:
• process measures such as recruitment rate and
specialist care attendance rate
• outcome measures such as identification rates of
FH and proportion of confirmed FH patients treated
to target
• Reducing premature CHD is the prime target of FH
screening1, 3, 9.
• The false positive diagnostic rate44 is a potential
harm but better use of algorithms (FAMCAT36 and
TARB-Ex33) may increase specificity
• The psychological impact of a diagnosis is
considered minimal but evidence for short-term
increase in anxiety is recognised 56, 57

(10) The overall
benefits of screening
should outweigh the
harm.

Cholesterol testing is offered as part of routine
clinical care - implications for testing and detection of
FH may not be appreciated initially 45.

1
2

FH: Familial hypercholesterolaemia

3

CHD: Coronary Heart Disease

4

DLCN: Dutch Lipid Clinic Network

5

MEDPED: Make Early Diagnosis to Prevent Early Deaths

6

S-B: Simon-Broome

7

NPAAC: National Pathology Accreditation Advisory Council

8

DNA: Deoxyribonucleic Acid

9

NGS: Next Generation Sequencing

10

FAMCAT: Familial Hypercholesterolaemia Case Ascertainment Tool

11

Page 27 of 29

1
2

Table 2. Tentative recommendations for screening by age for FH in primary
care
Age (years)

Cholesterol
Testing

Genetic
Testing

CASCADE
testing if
patient is
index case

0-2

No, unless
both parents
have high
cholesterol

Both parents
gene positive

Test parents
and siblings

2-11

> 2 years with
positive family
history;
otherwise
between age 5
and 11 by
guidelines
If not tested
previously,
optimally by
age 21 years

LDL-c > 190
mg/dL and
positive family
history

Test parents
and siblings

Meet S-B,
DLCN,
MEDPED or
other criteria
for phenotypic
FH
Meet S-B,
DLCN,
MEDPED or
other criteria
for phenotypic
FH
Meet S-B,
DLCN,
MEDPED or
other criteria
for phenotypic
FH

Test parents
and siblings

Parent or
sibling gene
positive

Test all first
degree
relatives

Parent, sibling,
or child gene
positive

Test all first
degree
relatives

Child or sibling
gene positive

12-30

30-60

Per adult
guidelines

> 60

Per adult
guidelines

CASCADE
testing if first
degree
relative
positive
Both parents
positive
(elevated
cholesterol or
gene positive)
Parent or
sibling gene
positive

3
4

FH: Familial hypercholesterolaemia

5

LDL-c: Low Density Lipoprotein-cholesterol

6

S-B: Simon-Broome

7

MEDPED: Make Early Diagnosis to Prevent Early Deaths

8

DLCN: Dutch Lipid Clinic Network

9
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Table 3. Knowledge gaps and suggestions for future research on FH screening
in primary care.
Science: Analytical Methods
• Assessment of role cholesterol gene scores in testing for FH
• Development of point-of-care lipid testing - total and LDL-cholesterol
and Lp(a)
• Development of point-of-care DNA testing
• Compare genomic strategies Sequence vs Chip & Sequence
Epidemiology
• Identification of new gene founder populations
• Genetic epidemiology of FH in diverse communities
• Development and application of registries
• Development and testing of universal screening protocols
• Data linkage studies between primary care and specialist databases
Clinical Research (diagnostics, risk prediction, intervention trials)
• Risk communication of genetic variants
• Role of risk prediction algorithms in screening for FH
• Clinical trials of screening protocols and testing interventions
• Enhancing cascade testing methods in the community
• Perceptions and psychological sequelae of genetic testing
• Development of new selective screening protocols
• Enhancing the use of information technology in case detection
Patient-centric
• Health literacy and understanding of genomics and genetic testing
• Education of public and patients on genomics and role in healthcare
• Insurance implications of genetic testing
• Public consultations regarding screening methods for FH
• Advocacy for raising awareness about genomics and genetic testing
Models of Care
• Education of primary care health professionals in genomic medicine
• Development and testing of primary care based models
• Roles of Specialists, General Practitioners, Practice nurses and
Pharmacists in detection and follow-up
• Design of education, training and accreditation programs in genomic
medicine
• Incorporation of cascade testing for Lp(a) within a primary care model

3
4

FH: Familial hypercholesterolaemia

5

LDL: Low Density Lipoprotein

6

Lp(a): Lipoprotein(a)

7

DNA: Deoxyribonucleic Acid

8
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